Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Sosei R&D Ltd.

Home Clinical Trial Sponsors and OrganizationsSosei R&D Ltd.

Sosei R&D Ltd.

ACTIVE

United Kingdomsosei.comPrivate51–100 employeesEstablished: 2000-01-01

Part of Sosei Co. Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

12

11 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2000

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Active, not recruiting

11

91.7%

Recruiting

1

8.3%

Clinical Trials

Trials sponsored by this organization (12)

Ensayo multicéntrico, aleatorizado, doble ciego, con doble simulación y cruzado, para evaluar la seguridad y la eficacia de AD 923 (Fentanilo sublingual) en comparación con sulfato de morfina de liberación inmediata (SMLI) en el tratamiento del dolor irruptivo en sujetos con procesos malignos.

Mar 2010150 participants

A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies

Active, not recruiting

Jan 2008300 participants

Ensayo multicéntrico, abierto y de extensión para evaluar la seguridad y la eficacia de AD 923 (Fentanilo sublingual) en el tratamiento del dolor irruptivo en sujetos con procesos malignos.

Active, not recruiting

Nov 2007300 participants

A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with Malignancies

Active, not recruiting

Nov 2007150 participants

A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies

Active, not recruiting

Nov 2007300 participants

A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with Malignancies

Active, not recruiting

Nov 2007150 participants

A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies

Active, not recruiting

Nov 2007300 participants

A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with Malignancies

Active, not recruiting

Nov 2007150 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials12
Approvals
News

Back to Organizations